Navidea Biopharma files Lymphoseek at EMA for Intraoperative Lymphatic Mapping
Navidea Biopharmaceuticals, Inc. a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, has announced that it has submitted a Marketing Authorization Application for its investigational radiopharmaceutical Lymphoseek (technetium Tc 99m tilmanocept) injection, a novel intraoperative lymphatic mapping agent, to the European Medicines Agency. Lymphoseek is used in intraoperative lymphatic mapping , a surgical oncology procedure used primarily in patients with breast cancer and melanoma to determine if disease has spread to the lymph nodes. Navidea Biopharmaceuticals has received a Complete Response Letter from the FDA in relation to its US application.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins